BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Prothena Corporation plc Announces Pricing of Public Offering of 5,910,000 Ordinary Shares


10/3/2013 9:59:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that it has priced an underwritten public offering of 5,910,000 of its ordinary shares at a price of $22.00 per ordinary share, before underwriting discounts and commissions. Of these ordinary shares, Prothena is offering 3,500,000 ordinary shares and Janssen Pharmaceutical, a wholly owned subsidiary of Johnson & Johnson, as selling shareholder, is offering 2,410,000 ordinary shares. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 886,500 ordinary shares. If the option is exercised in full, Prothena will issue and sell an additional 677,079 ordinary shares and Janssen Pharmaceutical will sell an additional 209,421 ordinary shares, which represents all of Janssen's shareholdings in Prothena.

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES